halcinonide and Dermatitis

Topics: Clinical Trials as Topic; Clobetasol; Dermatitis; Halcinonide; Humans; Pregnenediones; Psoriasis

Halcinonide-neomycin-amphotericin (HNA) cream was evaluated in the treatment of cutaneous candidiasis and inflammatory dermatoses. The anti-candidal properties of HNA were assessed in a parallel comparison with iodochlorhydroxyquin-hydrocortisone (I-HC) as the control drug. The overall therapeutic response with HNA was excellent in 38 (95%) of 40 patients as compared to 17 (43%) of 40 treated with I-HC. In 50 patients treated for psoriasis, eczematous dermatitis, or neurodermatitis, HNA was evaluated in a paired comparison with hydrocortisone (HC). The overall therapeutic response with HNA was excellent in 36 (72%) patients as compared to 18 (36%) with HC. There were no adverse reactions with HNA or the control drugs.

Topics: Administration, Topical; Adolescent; Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Candidiasis, Cutaneous; Child; Clinical Trials as Topic; Clioquinol; Dermatitis; Drug Combinations; Female; Halcinonide; Humans; Hydrocortisone; Male; Middle Aged; Neomycin; Pregnenediones; Time Factors

Topics: Balneology; Complementary Therapies; Dermatitis; Dermatologic Agents; Drug Contamination; Female; Glucocorticoids; Halcinonide; Humans; Mineral Waters; Nonprescription Drugs; Sodium Chloride; Triamcinolone

Halcinonide solution, 0.1 percent, was used to treat sixty-six patients with eczematous dermatoses. The majority of the responses were excellent, with the condition clearing completely in eight patients within the first week. The total mean amount of medication used by each patient for twice a day application for one or two weeks was less than 24 ml.

Topics: Adult; Dermatitis; Dermatitis, Seborrheic; Eczema; Eczema, Dyshidrotic; Female; Halcinonide; Humans; Male; Pregnenediones

An open evaluation of halcinonide 0.1 percent in a hydrophilic vanishing cream base was conducted in one hundred patients with common steroid-responsive dermatoses, including eczema, contact dermatitis, atopic dermatitis stasis dermatitis, and neurodermatitis. Patients applied the cream two or three times a day for two weeks (or less if the clinical response warranted earlier discontinuation). Follow-up assessments were made on days 4, 7, and 14 of the study. Ninety-eight percent of the patients showed some degree of improvement, and eighty-five percent had complete clearing or marked improvement. One patient had no response and one worsened. Seventy-seven percent of the patients who responded achieved their maximum response within the first week of treatment. One case of urticaria was the only side effect noted in this series. Ninety-six percent of the patients rated their acceptance of the new formulation as excellent or good.

Topics: Adolescent; Adult; Aged; Child; Dermatitis; Drug Evaluation; Female; Halcinonide; Humans; Male; Middle Aged; Ointment Bases; Pregnenediones